X4 Pharmaceuticals, Inc. Common Stock
Symbol: XFOR (NASDAQ)
3.47
▼ (-4.67%) -0.170
Company Description:
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Key Stats
- Today's Open: $3.55
- Today's High: $3.695
- Today's Low: $3.345
- Today's Volume: 540.93K
- Yesterday Close: $3.64
- Yesterday High: $3.79
- Yesterday Low: $3.0235
- Yesterday Volume: 1.32M
- Last Min Volume: 43
- Last Min High: $3.47
- Last Min Low: $3.47
- Last Min VWAP: $3.47
Company Profile
- Name: X4 Pharmaceuticals, Inc. Common Stock
- Website: https://www.x4pharma.com
- Listed Date: 2017-11-16
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001501697
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $78.57M
- Round Lot: 100
- Outstanding Shares: 22.45M
- Asset Type: CS
RECENT FILINGS FOR XFOR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-25 | D | View |
| 2025-08-25 | 8-K | View |
| 2025-08-20 | SCHEDULE 13G | View |
| 2025-08-19 | SCHEDULE 13G | View |
| 2025-08-18 | SCHEDULE 13G | View |
| 2025-08-18 | SCHEDULE 13D | View |
| 2025-08-15 | SCHEDULE 13D/A | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13D | View |
| 2025-08-13 | 8-K | View |
| 2025-08-12 | 8-K | View |
| 2025-08-08 | 10-Q | View |
| 2025-07-18 | SCHEDULE 13G/A | View |
| 2025-07-03 | 4 | View |
Latest News on XFOR